Geron Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Dawn Bir
Chief executive officer
US$583.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.9yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Geron Corporation's (NASDAQ:GERN) Shares Climb 30% But Its Business Is Yet to Catch Up
Jun 13
Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade)
Jun 11Analysts Have Lowered Expectations For Geron Corporation (NASDAQ:GERN) After Its Latest Results
May 10
EU Approval And US Initiatives Will Expand Future Markets
European expansion with RYTELO's approval and launch could significantly boost revenue through international growth and increased market reach.Is Geron (NASDAQ:GERN) A Risky Investment?
Apr 17Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments
Mar 31Geron Corp: How Concerned Should We Be About Rytelo Sales?
Mar 17Risks Still Elevated At These Prices As Geron Corporation (NASDAQ:GERN) Shares Dive 45%
Mar 12We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely
Feb 27Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales
Feb 26Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
Feb 03Geron: A Post Earnings And Funding Announcement Assessment
Nov 07Is Geron (NASDAQ:GERN) Using Too Much Debt?
Oct 28Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)
Aug 12Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition
Jul 31Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?
Jul 12Geron: Innovative Rytelo Enters A Challenging MDS Market
Jun 08Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All
May 03Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
Mar 15Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Mar 05Is Geron (NASDAQ:GERN) A Risky Investment?
Aug 25CEO
Dawn Bir (54 yo)
Ms. Dawn Carter Bir is a Director at Soleno Therapeutics, Inc. since August 12, 2024. She was Chief Commercial Officer of Reata Pharmaceuticals, Inc. since September 2016 and oversee marketing, market acce...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim President & Chief Executive Officer and Director | less than a year | US$583.31k | no data | |
| Executive VP | 1.8yrs | US$2.15m | 0% $ 0 | |
| Executive VP & COO | 6.5yrs | US$2.81m | 0.00036% $ 3.0k | |
| Executive VP & Chief Commercial Officer | less than a year | US$5.77m | 0.016% $ 129.0k | |
| Executive Vice President of Research & Development | less than a year | US$7.21m | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Executive VP | 1.9yrs | US$3.61m | 0.0042% $ 34.4k | |
| Executive VP & Chief People Officer | 6.1yrs | no data | no data | |
| Executive VP & Chief Medical Officer | 3yrs | no data | no data |
Experienced Management: GERN's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim President & Chief Executive Officer and Director | 6.3yrs | US$583.31k | no data | |
| Independent Director | 1.7yrs | US$589.84k | 0% $ 0 | |
| Independent Director | 13.3yrs | US$586.66k | 0.0021% $ 17.2k | |
| Lead Independent Director | 6.3yrs | US$630.75k | 0.0053% $ 43.4k | |
| Independent Director | 15.2yrs | US$583.32k | 0.029% $ 235.9k | |
| Independent Director | 12.8yrs | US$582.47k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$588.25k | 0% $ 0 |
Experienced Board: GERN's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/18 13:20 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Geron Corporation is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carter Gould | Barclays |
| Peter Lawson | Barclays |
| George Zavoico | B. Riley Securities, Inc. |